Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan administration details.
Specific transaction data includes the re-investment of notional dividends on July 8, 2013, at the following average prices:
- 2010 Plan Awards: 1360.50 pence per Ordinary Share; $42.908 per ADS
- 2011 Plan Awards: 1413.90 pence per Ordinary Share; $44.867 per ADS
- 2012 Plan Awards: 1459.00 pence per Ordinary Share; $46.286 per ADS
Material Changes
The filing reports an increase in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for various executives. This change reflects a reconciliation of notional dividends following a change in Plan administration to ensure the originally intended number of notional dividends accrues over the relevant vesting periods.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the impact of the Plan administration change on future vesting calculations for the 2010, 2011, and 2012 Performance Share Plan awards.
- Confirm the specific number of Ordinary Shares and ADSs allocated to each named director and executive as listed in the notification.
- Note that notional dividends accrued will be paid out only in proportion to the percentage of holdings that vest following the end of the relevant measurement period.